Unraveling the effects of glycerophosphoinositol-enriched hyaluronic acid eyedrops on the ocular surface in glaucoma: a report from the multicenter OSGLA registry
Frontiers in Medicine · 06.08.2026 · 13
DOI: 10.3389/fmed.2026.1868619 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Medicine, online erschienen am 06.08.2026. Verfasst von Luca Agnifili und 9 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology Clinic, Department of Medicine and Ageing Science, University "G. d'Annunzio" of Chieti-Pescara, Chieti, Italy. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To evaluate the effects of 0. 001% glycerophosphoinositol in 0.2% hyaluronate (GPI/HA) vehicle eye drops in patients with glaucoma therapy related-ocular surface disease (GTOSD).
Methods
Forty patients diagnosed with GTOSD and receiving GPI/HA or HA 0.2%, underwent ocular surface disease index (OSDI), Symptom Assessment iN Dry Eye (SANDE), National Eye Institute Visual Function Questionnaire (NEI VFQ)-25 questionnaires, and tear matrix metalloproteinase-9 (MMP-9), break-up time (BUT), corneal fluorescein staining (CFS), Schirmer test I (STI), and bulbar conjunctival hyperemia (BCH) determination Results After 1 month, GPI/HA eyedrops increased BUT [6 (4–7.25) to 7 (6–8)] and STI [11.5 (8–17.5) to 13.5 (10–18.5)], whereas decreased BCH [2.2 (2.1–2.3) to 2.1 (1.3–2.2)] and CFS [3 (2–4) to 2 (2–3)] ( p < 0.001). Questionnaire scores improved from 35 (24.36–46.25) to 33 (20.75–40.52), for SANDE and from 31.5 (20–45) to 28.5 (17.75–40.5), for OSDI ( p < 0.001). HA 0.2% eyedrops reduced BCH from 2.75 (2.15–3.20) to 2.25 (1.90–2.30) and CFS from 3.5 (2.75–5) to 2.5 (2–4) ( p = 0.014), and increased BUT ( p = 0.036). Questionnaire scores improved from 28.95 (20.9–47.6) to 26.86 (19.90–36.41) ( p = 0.009) for SANDE, and from 40 (19.5–49) to 29 (19.75–42) ( p = 0.005) for OSDI. There were not significant modifications in the MMP-9 immunoassay positivity in either treatment group. Follow-up inter-group comparisons showed better BCH values in GPI/HA, and better NEI VFQ-25 scores in HA 0.2%.
Conclusion
Both treatments proved valuable in managing GTOSD, supporting the use of lubricants in this condition. GPI/HA showed a broader pattern of improvement, which should be interpreted cautiously given the observational design and limited inter-group differences.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ophthalmology Clinic, Department of Medicine and Ageing Science, University "G. d'Annunzio" of Chieti-Pescara, Chieti, Italy.
- Alma Mater Studiorum, University of Bologna, Bologna, Italy.
- Ophthalmology Clinic, SS Annunziata Hospital, Chieti, Italy.
- Ophthalmology Clinic, Department of Neuroscience, Imaging and Clinical Science, "G. d'Annunzio" University Chieti-Pescara, Chieti, Italy.
- IRCCS Fondazione Bietti, Rome, Italy.
- Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
Zitieren
APA
Agnifili, L., Celani, D., Ruggeri, M. L., Sferra, A., Mastropasqua, R., Oddone, F., Carnevale, C., Pinna, A., Figus, M., & Sacchi, M. (2026). Unraveling the effects of glycerophosphoinositol-enriched hyaluronic acid eyedrops on the ocular surface in glaucoma: a report from the multicenter OSGLA registry. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1868619
Vancouver
Agnifili L, Celani D, Ruggeri ML, Sferra A, Mastropasqua R, Oddone F, et al. Unraveling the effects of glycerophosphoinositol-enriched hyaluronic acid eyedrops on the ocular surface in glaucoma: a report from the multicenter OSGLA registry. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1868619
BibTeX
@article{Agnifili2026,
author = {Agnifili, Luca and Celani, Davide and Ruggeri, Maria Ludovica and Sferra, Alessandro and Mastropasqua, Rodolfo and Oddone, Francesco and Carnevale, Carmela and Pinna, Antonio and Figus, Michele and Sacchi, Matteo},
title = {Unraveling the effects of glycerophosphoinositol-enriched hyaluronic acid eyedrops on the ocular surface in glaucoma: a report from the multicenter OSGLA registry},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.1868619}
}
EUVIMED